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AbsTrACT Early diagnosis and therapy of precancerous lesions and malignant 
tumors belong to the most challenging tasks in modern medicine. Photodynamic 
diagnosis can help diagnose both precancerous lesions and early carcinoma. 
Actinic keratosis (AK) is the most common precancerous lesion of the skin. The 
available data show a high effectiveness of diclofenac in treating multifocal AK. 
We report a case of a 52-year-old woman who complained of multiple dissemi-
nated AK lesions predominantly on the lower limbs and trunk with a significant 
exacerbation within the last 6 months. Due to the spreading of disease and a high 
number of AK foci, as well as technical problems with visiting the hospital (PDT 
Laboratory), photodynamic therapy was not applied. The patient was treated for 
2 months with a combination of local administration of 3% diclofenac and 0.1% 
tazaroten and 3% diclofenac only as a half side (left-right) comparison. The effects 
of therapy were later clinically evaluated and verified by means of photodynamic 
diagnosis (PDD) directly after therapy and at a follow-up examination 3 months 
later. The evaluation of treatment was blinded.
Treatment with diclofenac only on the right side of the body resulted in clearing 
of 55% of all treated lesions, which increased to 60% three months after finishing 
therapy. On the left side of the body, where combined therapy (diclofenac 2 times 
daily on uneven dates and diclofenac once a day + tazaroten once a day on even 
dates) was used, 77.5% pathologic lesions disappeared, but this did not increase 
at follow up.
The treatment of multifocal, disseminated AK is a difficult task and also burden-
some for the patient due to side effects like scarring or burning and itching which 
occur during most therapies. Combined therapy with diclofenac and tazaroten 
supported by PDD may improve the effects of routine treatment of AK.
KEy worDs: actinic keratosis, diclofenac, tazaroten, photodynamic diagnosis 
InTroDUCTIon
Early diagnosis and therapy of precancerous dis-
orders and malignant tumors belongs to the most 
challenging tasks in the modern medicine. Treatment 
methods are often comprised of a combination of 
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biological, chemical, physical, and pharmacological 
approaches. Photodynamic diagnosis (PDD) can help 
diagnose both precancerous lesions and early cancer 
and enables the evaluation of the effectiveness of 
other previously applied therapeutic methods, e.g. 
surgery or photodynamic therapy (PDT). The founda-
tion of PDD is the fluorescence of photosensitizing 
drug which is administered systemically or locally and 
sensitized with light at 405 nm (1-3). PDT has been 
used successfully for many years in dermatology and 
for malignant and non-malignant diseases (4,5). This 
method received much attention because of its ther-
apeutic and cosmetic effects that made this therapy a 
treatment of choice in a number of maladies.
Actinic keratosis (AK) is the most common precan-
cerous lesion of the skin and 0.1-15% of develop into 
a skin squamous cell carcinoma (SCC) (6). AK usually 
develops in open skin areas: the face, neck, and limbs, 
and it presents as hyperchromatic (overcolored), yel-
low-brownish, hyperkeratotic lesions (7). When its 
keratotic layer is removed, AKs show a bleeding sur-
face. These lesions grow slowly and last for years be-
fore malignant transformation can occur.
Long sun exposure related to work, sun-baths, 
and a bright skin phototype predispose to AK (6).
Cryotherapy, laser therapy, and photodynamic 
therapy (PDT) as well as local application of cytotoxic 
preparations (podofilotoxin, fluorouracil) and imiqui-
mod, a local immunomodulator, are common meth-
ods of treatment of AK (8-9).
More invasive methods can lead to scarring, so 
therapy for multifocal AK can also cause cosmetic 
problems (10,11). Locally acting preparations, e.g. 
imiquimod, often cause pain and thus the patients 
discontinue treatment (12,13).
During recent years 3% diclofenac gel (Solaraze®) 
was introduced to AK therapy in the USA, Canada, 
and some European countries, with promising results 
(14). This preparation is a non-steroidal anti-inflam-
matory drug (NSAID) and inhibits cyclooxygenase-2 
(COX-2) thus reducing prostaglandin synthesis which 
is commonly elevated in AK patients (15,16).
The available data show a high effectiveness of 
diclofenac in treating multifocal AKs with positive re-
sponses at 40 to 85% and with relatively small side 
effects (17-19).
Retinoids are a group of drugs which was intro-
duced to dermatology in the 1980s and is comprised 
of retinol (vitamin A derivative) and its analogs. Reti-
noids are used in medicine because they influence 
epithelial cell growth and differentiation, and regulate 
apoptosis through the activation of genes via nuclear 
receptors, RAR and RXR (20,21). Tazaroten belongs to 
the new generation of retinoids. It has a specific affin-
ity to RAR receptors, and thus regulates proliferation 
and differentiation of the cells. Tazaroten inhibits ara-
chidonic acid pathway and reduces inflammatory re-
actions, and also regulates the keratinization process 
(22,23). Unlike other retinoids, tazaroten is well toler-
ated by the skin. In dermatology, it is mainly used in 
treating psoriasis and acne vulgaris (24,25).
By analyzing the characteristics and effects of di-
clofenac and tazaroten, authors decided to investi-
gate whether their use will increase the overall effec-
tiveness of the treatment of numerous, disseminated, 
and eruptive AK in a patient with chronic exposure 
to sunlight. We report a case of a 52-year-old woman 
with multiple disseminated AK lesions. 
PATIEnTs AnD mEThoDs
A 52-year-old woman was admitted to the Pho-
todynamic Therapy Laboratory because of multifocal 
actinic keratosis (AK) which had occurred predomi-
nantly on the lower limbs and trunk during the last 3 
years with a significant exacerbation within the last 6 
months (Figure 1). 
Due to the spreading of disease and high number 
of AK foci and technical problems with visiting the 
hospital (PDT Laboratory), PDT was not applied.
The lesions were coarse, grey-yellowish, and 
oozed when rubbed. For the last 10 years the patient 
had spent a lot of time working in the sunlight dur-
ing the summer in southern Europe. She had a bright 
skin phototype and presented with skin photoaging, 
i.e. telangiectatic lesions, deep wrinkles, and over 
coloring of the skin. The patient had not used any 
protection against UV radiation. She often got severe 
sunburns; her economic status did not allow her to 
avoid this type of field work. The patient felt generally 
Figure 1. Disseminated actinic keratosis lesions on 
the lower limbs before therapy.
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healthy, however, and had been drinking tea with St. 
John’s wort every day, which reportedly helped her 
digestion.
The therapy was performed as a half side (left-
right) treatment. Ten areas of the skin, each 5 cm2 
large with 2-4 AK lesions, were arbitrarily chosen on 
each side of the body. The areas contained altogether 
27 lesions on the left and 33 lesions on the right. The 
lesions on the right side were treated using 3% diclof-
enac gel at 0.5 g per area, two times daily. On the left 
side, in addition to diclofenac once per day, 0.1% taz-
aroten cream was applied in the evening every other 
day (Table 1). The schedule of therapy was as follows: 
diclofenac two times daily on uneven dates, and on 
even dates diclofenac in the morning and tazaroten 
in the evening, for 60 days. Due to a difficult personal 
economic situation the patient had to stop treatment 
after 2 months since she was doing seasonal work 
outside the country. 
A clinical control examination was carried out 
directly after the start of the treatment, and then 3 
months later. The professional who evaluated the ef-
fect of treatment was not informed how the drugs 
were administered. The effectiveness of the treat-
ment was evaluated in two ways:
A) Clinically, with relation to the total responses 
(complete disappearing of AK foci in treated skin ar-
eas) directly after treatment and three months after.
B) Using photodynamic detection (PDD), which 
verifies clinical evaluation. A control PDD examina-
tion was also carried out directly after finishing treat-
ment and three months after.
Levulan® Kerastick® (DUSA Pharmaceuticals) was 
used in this study. The AK lesions were treated with 
the cream under occlusion, and irradiated 1.5 hours 
later with a blue light (405 nm) from a halogen light 
source (Penta Lamps, Teclas). Red fluorescence was 
observed in pathological lesions.
rEsUlTs
In the course of treatment with 3% diclofenac the 
main reported symptoms were itching, dry skin, and 
erythema. Symptoms in areas subjected to treatment 
with 0.1% tazaroten were dryness, burning, and ery-
thema which increased during the first two weeks 
and then disappeared. The results of monotherapy 
and combined therapy are shown in Table 1. We ob-
served no increase in hyperpigmentation after treat-
ment.
Figure 2 shows lesions on the right side of the 
body before treatment, during a photodynamic di-
agnosis session. The effectiveness of the treatment 
using only diclofenac on the right side of the body 
amounted to 55% (i.e. 55% of complete responses to 
the therapy). After 30 days from the end of treatment, 
the number of cured lesions increased to 60%. Con-
trol examination using PDD three months after treat-
ment revealed a single red fluorescing foci in 3 areas 
which were treated with diclofenac only (Figure 3).
On the left side of the body where combined 
Table 1. Treatment procedure and effect, PDD examination
Effect of AK therapy  
(total response) in % 
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therapy (diclofenac 2 times daily on uneven dates 
and diclofenac once a day + tazaroten once a day on 
even dates) was used, 77.5% of pathological lesions 
disappeared (i.e. 77.5% complete responses to the 
therapy). Some lesions disappeared rapidly within 
6 weeks, though the application of diclofenac and 
tazaroten continued until the end of scheduled treat-
ment protocol, i.e. for 60 days. Results of PDD after 
3 months are shown in Figure 4 no red fluorescence 
was observed. There was no further reduction in the 
pathological AK foci during the next 3 months after 
therapy, and thus the rate of complete responses was 
still 77.5%. PDD did not reveal new pathological le-
sions in areas treated with combined therapy. 
DIsCUssIon
Actinic keratosis  is one of the most frequent pre-
cancerous lesions in humans, and is attributed to 
prolonged exposure to UV radiation. It mainly affects 
older people, and the lesions occur progressively over 
many years. Actinic keratosis occurs predominantly in 
areas of the skin that are exposed to the sunlight.
In our case the AK foci also occurred in areas pro-
tected by clothes, i.e. on the trunk and lower limbs. 
A dynamic dissemination of lesions was observed 
over a very short period of time, i.e. in 6 months. The 
AK localized in areas such as the trunk and limbs is 
predisposed to squamous cell carcinoma. The reason 
why these lesions grow so fast is not known. There 
are reports in which the eruptive type (form) of AK 
was described, e.g. after heart transplantation or in 
patients with Kindler syndrome, a genodermatosis 
with hypersensitivity to the light (26-28). In multifo-
cal AK the application of immunomodulator, imiqui-
mod (Aldara®) is highly recommended (29-31). The 
contraindication to imiquimod is an impairment of 
immunological mechanisms (32,33). For the same 
reason (rapid eruption of lesions suggests immuno-
deficiency) the authors rejected the application of 
the cytostatic 5-fluorouracil.
In this study we used monotherapy with 3% di-
clofenac and a combined therapy using the above 
preparation and tazaroten. Diclofenac gel, which was 
approved for treating multifocal AK is a safe and well 
tolerated preparation. The patient bore this therapy 
well and the local undesired symptoms, such as burn-
ing and redness of the skin that usually occur during 
the therapy using diclofenac, were transient. The 
reported effectiveness of the treatment of AK with 
Diclofenac uneven – it varies from reducing the size 
to complete disappearance of lesions. Rivers et al. re-
ported a very high efficacy of AK treatment with 5% 
Imiquimod cream. Fifty percent of patients experi-
enced complete clearance of AK lesions, and 75% of 
patients experienced partial clearance of AK lesions 
after imiquimod treatment (34). Fariba et al. reported 
a complete eradication of lesions in only 9.3% and re-
duction in 65% of cases after using 3% diclofenac in 
Figure 4. Photodynamic diagnostics three months 
after therapy with diclofenac and tazaroten showed 
no red fluorescence.
Figure 2. Photodynamic diagnostics of actinic kerato-
sis lesions before therapy (intense red fluorescence).
Figure 3. Photodynamic diagnostics three months 
after therapy with diclofenac only revealed a single 
red fluorescing foci in 3 areas.
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2.5% hyaluronan gel (35). Nelson et al. reported high 
effectiveness of treatment for AK in 78% of patients 
(36). Berlin and Rigel combined application of diclof-
enac with cryotherapy and found that this modifica-
tion increased the effects from 21% to 46% (37).
The combination of diclofenac with tazaroten in 
our study increased successful treatment of the lesions 
to 77.5% in comparison with the 60% from mono-
therapy. The control PDD examination 3 months after 
therapy confirmed stable therapeutic effects for the 
combined method (see Table 1). Monotherapy using 
diclofenac gel did not prevent recurrent lesions that 
fluoresced in 3 treated areas 3 months after therapy. 
The treatment of multifocal, disseminated AK is 
a difficult task and also burdensome for patients be-
cause of side effects that include burning and itching. 
Frequently, the patients discontinue pharmacological 
treatment because of the above symptoms. The erad-
ication of more intense lesions using more aggressive 
methods can cause scarring and over coloring of the 
skin, which is often unacceptable to patients. There-
fore, it is necessary to search for new effective thera-
peutic methods. The combination of two preparations 
– an anti-inflammatory drug, diclofenac, and tazaro-
ten that regulates growth and differentiation of cells 
– resulted in promising therapeutic effects. Increas-
ing side effects which were caused by tazaroten, i.e. 
burning pain and skin dryness, disappeared within 2 
weeks. Due to the above complications tazaroten was 
applied once a day in the evening every second day. 
The promising effects of the therapy in this patient 
encourage application of this combined treatment 
for multifocal AK especially when imiquimod and 5-
fluorouracil are used, because the impairment of the 
immune system must be excluded. Photodynamic 
therapy was planned as a continuation of the treat-
ment, which did not take place due to the patient’s 
trip abroad. After half a year, we received information 
from the family that the patient was operated for a 
tumor of the gastrointestinal tract, and contact with 
the patient was lost.
With this report we would like to emphasize the 
effectiveness of PDD in dermatooncologic diagnos-
tics. Sieroń et al stressed the significance of PDD and 
PDT in treating tumors (38). Other reports supported 
those findings, especially in relation to evaluation of 
tumor margins, effects of therapy and follow-ups (39-
41). PDD, in contrast with histological examination, is 
an optical method and thus this does not require tis-
sue biopsies. Clinical applications of PDD in diagnosis 
are still uncommon. Our intention was to draw the 
attention of practitioners to the usefulness of PDD 
in evaluating the effects of treatment and long-term 
observations in patients with skin disorders treated 
with different methods. 
ConClUsIon
This case suggests that further clinical studies on 
the effectiveness of local combined therapy in treat-
ing multifocal AK are needed.
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